Asymmetric GPR84 antagonists and their uses
By designing GPR84 antagonists with asymmetric structures, the problems of poor oral absorption and uneven organ distribution of existing compounds have been solved, resulting in better therapeutic effects.
Patent Information
- Application Number
- CN202280047121.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2021-07-15
- Filing Date
- 2022-07-13
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2042-07-13
AI Technical Summary
Existing GPR84 antagonists suffer from symmetry limitations in their compound structure, resulting in poor oral absorption and uneven distribution to organs, making them difficult to effectively treat diseases such as multiple sclerosis, inflammatory bowel disease, and arthritis.
A class of asymmetric GPR84 antagonists was designed, in which one ester group of the phosphate diester is a tricyclic fragment, and the other ester group is derived into various structural types, such as (cyclo)alkyl or substituted (cyclo)alkyl, aryl or substituted aryl, and bile acid derivatives. The CLogP of the compound was optimized to improve oral absorption and targeted distribution characteristics.
This study achieved improvements in the oral absorption and targeted distribution characteristics of GPR84 antagonists while maintaining their activity, thereby enhancing their therapeutic effects on diseases such as multiple sclerosis, inflammatory bowel disease, and arthritis.
Smart Images

Figure CN117715920B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to a class of ligand molecules for G protein-coupled receptor 84 (GPR84). The ligand molecules involved in this invention possess antagonistic activity against GPR84, competitively inhibiting the receptor activation effect induced by GPR84 agonists. They can be used to treat various diseases associated with high GPR84 expression or excessive excitability, such as multiple sclerosis, inflammatory bowel disease, organ fibrosis, and arthritis. Background Technology
[0002] GPR84, discovered in 2001, is a G protein-coupled receptor that couples to the Gi pathway. It can be activated by medium-chain fatty acids (MCFAs) with a chain length of C9-C14. Activation of GPR84 inhibits adenylate cyclase, leading to reduced cAMP production. GPR84 is expressed in various tissues and organs, such as the heart, lungs, kidneys, liver, bone marrow, and adipose tissue, particularly in myeloid cells related to the innate immune system, including monocytes, macrophages, and neutrophils in peripheral blood, as well as microglia in the central nervous system. Under physiological conditions, GPR84 expression is low in leukocytes and adipocytes, but acute inflammatory stimuli (such as lipopolysaccharide (LPS), TNFα, or inflammatory responses associated with many diseases) can induce a significant upregulation of GPR84 expression. GPR84 activation can enhance the phagocytic activity of macrophages, promote the chemotaxis of immune cells, and increase the secretion of pro-inflammatory cytokines (IL-12 p40), thereby amplifying the body's inflammatory response. On the other hand, GPR84 knockout leads to a decrease in the secretion of pro-inflammatory cytokines (IL-1, IL-6, and TNF) in macrophages, while increasing the secretion of Th2 cytokines (IL-4, IL-5, and IL-13) in T cells. The above studies have confirmed the pro-inflammatory role of GPR84 in metabolic regulation and immune response. Subsequent studies have revealed that GPR84 is associated with the development and progression of various inflammatory and metabolic diseases, such as multiple sclerosis (MS, Glia 2007, 55, 790-800), inflammatory bowel disease (IBD, J. Med. Chem. 2020, 63, 13526-13545), organ fibrosis (J. Clin. Med. 2020, 9, 4, Am. J. Pathol. 2018, 188, 1132-1148), and arthritis (Curr. Opin. Clin. Nutr. Metab. Care 2011, 14, 322-327). Therefore, GPR84 is a potential target for the treatment of these diseases, and GPR84 antagonists hold promise for their therapeutic applications.
[0003] To date, only Galapagos (Belgium) and Liminal (Canada) have reported patents for GPR84 antagonists. Galapagos' compounds possess a tetrahydroisoquinoline pyrimidinone (or pyridone) structural core (WO2013092791, WO2014095798, WO2015197550, WO2016169911). A representative compound, GLPG1205, is a highly active GPR84 allosteric antagonist (J.Med.Chem.2020,63,13526-13545). It was previously a candidate drug for treating inflammatory bowel disease and entered a Phase II clinical trial, but the trial was terminated due to a lack of significant difference in efficacy compared to the placebo group. This compound is currently undergoing a second Phase II clinical evaluation for the treatment of idiopathic pulmonary fibrosis. Liminal's PBI-4050 and PBI-4547 are non-selective GPR84 antagonists. Their structures are sodium 3-n-pentylphenylacetate and sodium 3,5-di-n-pentylphenylacetate, respectively, both fatty acid analogs. Their antagonistic activity against GPR84 is at the micromolar level, while they also exhibit agonistic activity against fatty acid receptors GPR40 and GPR120. A phase II clinical trial of PBI-4050 for the treatment of idiopathic pulmonary fibrosis has been completed, and treatment is currently underway. Phase II / III clinical trials for the disease; PBI-4547 is currently undergoing Phase I clinical trials as a candidate drug for non-alcoholic steatohepatitis.
[0004] Nan Fajun et al. reported a class of highly active GPR84 antagonists (WO2018161831) with a phosphodiester structure, in which both ester groups are tricyclic. The representative compound, XYF573c, significantly alleviated DSS-induced enteritis symptoms in mice, showing superior efficacy compared to sulfasalazine at the same dose. Furthermore, tissue distribution studies showed that XYF573c selectively distributed in the intestine (AUC). 0-8h =24447.42 h*ng / mL, oral: 5 mg / kg), while the exposure in peripheral blood is relatively low (AUC). 0-8h =666.53 h*ng / mL (oral: 5 mg / kg). Therefore, XYF573c mainly works by inhibiting GPR84-mediated inflammatory responses by acting on upregulated GPR84 in intestinal immune cells, thus treating enteritis. Its distribution in peripheral blood suggests that it can also exert its effects by partially inhibiting the migration of peripheral immune cells. The intestinal-targeting distribution of such GPR84 antagonists indicates their suitability for the treatment of inflammatory bowel disease, but their poor oral absorption limits their application in the treatment of organ fibrosis, multiple sclerosis, arthritis, and other diseases.
[0005] The oral absorption of a compound is closely related to its lipid-water partition coefficients (such as CLogP and ALogP). Compounds with good drug-like properties need a CLogP of less than 5 (Lipinski's rule of fifths for drug-like properties), while XYF573c has a CLogP of 6.419, indicating significant room for optimization. In the phosphodiester structure of the original GPR84 antagonist, both ester groups are strongly lipophilic tricyclic structures. This symmetrical structural feature not only limits the expansion of the compound's chemical space but also greatly hinders the optimization of its drug-like properties (such as CLogP and ALogP). Summary of the Invention
[0006] The purpose of this invention is to provide a novel GPR84 antagonist, its preparation method, and its uses.
[0007] In a first aspect, the present invention provides a compound of general formula (I), or an enantiomer, diastereomer, racemate, or a pharmaceutically acceptable salt thereof.
[0008]
[0009] In the formula, Y represents O or S;
[0010] Z is H, or the ion of the following metals: Li, Na, K, Ca, Mg, Cu, Fe, Zn, Al, Mn, or the conjugate acid of the following bases: NH3, arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, aminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucosamine, histidine, hydroxycobalamin, isopropylamine, lysine, methylglucosamine, morpholine, piperazine, piperidine, polyamine resin, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, aminobutanetriol, imidazole;
[0011] L1 is free, O, S, -CH=CH-, -CO-, -C(=CH2)-, substituted or unsubstituted C1-C6 alkylene, -NH-, -N(C1-C4 alkyl)-, C3-C6 cycloalkyl or C3-C6 heterocycloalkyl, wherein the substitution refers to having one or more substituents selected from the group consisting of: C1-C6 alkyl, C1-C6 alkoxy, halogen, hydroxyl;
[0012] L2 is none, CH;
[0013] Rings A and B are each independently C6-C 10 Aromatic rings, C3-C 10 Cycloalkanes, C3-C 10 Heterocyclic alkane rings, C3-C 10 Mixed fragrance ring;
[0014] n1 and n2 are each independently 0, 1, 2, 3, or 4; R1 and R2 are each independently -OH, -SH, -NH2, F, Cl, Br, I, or substituted or unsubstituted -C. r H 2r -L7-C s H 2s+1 -C r H 2r -N(C t H 2t+1 )-C s H 2s+1 The substituted or unsubstituted C1-C6 alkyl group, wherein the substitution refers to having one or more substituents selected from the group consisting of: halogen, hydroxyl, amino, -COOC1-C6 alkyl, -COOH; L7 is independently O, S, NH, each r is independently 0, 1, 2, 3, 4, 5 or 6, each s is independently 0, 1, 2, 3, 4, 5 or 6, and each t is independently 1, 2, 3, 4, 5 or 6;
[0015] L3 and L4 are independently O, none, and -O (C1~C 10 Alkylene)-, -O(C1~C 10 Alkylene)NH-, -O(C1~C 10 Alkylene) O-, -CONH-, -OCO-, -NH-, -NHCOO-, -N(C1~C6 alkyl)-, or C1~C 10 Alkylene;
[0016] R3 can be H, OH, NH2, SH, -COOH, or a substituted or unsubstituted C1-C2 group. 10 Alkyl, substituted or unsubstituted C2-C 10 Alkenyl, substituted or unsubstituted C2-C 10 Alkyne group, substituted or unsubstituted 3-12 membered cycloalkanes, substituted or unsubstituted C6-C 14 Aromatic ring, substituted or unsubstituted amino group, substituted or unsubstituted 4-10 membered heterocyclic alkane ring, substituted or unsubstituted 4-10 membered heteroaromatic ring, cholic acid, lithocholic acid, deoxycholic acid, isolithocholic acid, isodeoxycholic acid, chenodeoxycholic acid, ursodeoxycholic acid, α-mouse cholic acid, β-mouse cholic acid, γ-mouse cholic acid, ω-mouse cholic acid; the above substitution refers to having 1, 2, 3, 4, 5 or 6 substituents selected from the group consisting of: amino, C1-C1, C2-C3, C4-C4, C5-C6 ... 10 Alkyl, halogen, C6-C 10 Aromatic rings, C1-C6 alkoxy groups, 3-12 membered cycloalkane rings, -OC p H 2p -OC q H 2q+1Nitro, oxo (=O), hydroxyl, carboxyl, -C(O)OC1~C6 alkyl, -O-C6-C 10 Aromatic ring, -NH-(4-10-membered heteroaryl ring), -NH-(4-10-membered heteroaryl ring)-CONH2; wherein each p is independently 1, 2, 3, 4, 5 or 6, and each q is independently 1, 2, 3, 4, 5 or 6;
[0017] each It can be used to represent a single bond or a double bond independently.
[0018] In another preferred embodiment, rings A and B are each independently a benzene ring, a C3-C6 cycloalkane ring, a C3-C6 heterocyclic alkane ring, or a C3-C6 heteroaromatic ring.
[0019] In another preferred embodiment, rings A and B are each independently a benzene ring, a thiophene ring, a pyrrole ring, a furan ring, a cyclohexane ring, a cyclopentane ring, or a cycloheptane ring.
[0020] In another preferred embodiment, L1 is independently none, CH2, O, S, -CO-, -NH-; L2 is independently none, CH.
[0021] In another preferred embodiment, n1 is 0, 1, or 2; R1 is F, Cl, Br, I, methoxy, ethoxy, n-propoxy, isopropoxy, or trifluoromethoxy.
[0022] In another preferred embodiment, n2 is 0, 1, or 2; R2 is F, Cl, Br, I, methoxy, ethoxy, n-propoxy, isopropoxy, or trifluoromethoxy.
[0023] In another preferred embodiment, L3 is O or S.
[0024] In another preferred embodiment, L4 is O, none, -NH-, -OCH2NH-, -OCH2CH2NH-, -OCH2CH2CH2NH-, -N(C1-C4 alkyl)-, -CH2- or -CH2CH2-.
[0025] In this invention, such as -O(C1~C 10 Alkylene)-, -O(C1~C 10 There are no particular restrictions on the connection method of alkylene groups such as NH-, -CONH-, -OCO-, -NHCOO-, -OCH2NH-, -OCH2CH2NH-, and -OCH2CH2CH2NH-. They can be connected to the adjacent atom or group, such as C, P, or R3, from left to right or from right to left. For example, for P-L4-R3, when L4 is -CONH-, it means P-CONH-R3 or R3-CONH-P. In another preferred embodiment, when L4 is defined as the above-mentioned group, the left end of the group is connected to P, and the right end is connected to R3.
[0026] In another preferred embodiment, R3 is a substituted or unsubstituted C1-C1. 10 Alkyl, substituted or unsubstituted C2-C 10 Alkenyl, substituted or unsubstituted C2-C 10 Alkyne group, substituted or unsubstituted 3-12 membered cycloalkanes, substituted or unsubstituted C6-C 14 Aromatic ring, substituted or unsubstituted amino group, substituted or unsubstituted 4-10 membered heterocyclic alkane ring, substituted or unsubstituted 4-10 membered heteroaromatic ring, cholic acid, lithocholic acid, deoxycholic acid, isolithocholic acid, isodeoxycholic acid, chenodeoxycholic acid, ursodeoxycholic acid, α-mouse cholic acid, β-mouse cholic acid, γ-mouse cholic acid, ω-mouse cholic acid; the above substitution refers to having 1, 2, 3, 4 or 5 substituents selected from the group consisting of: amino, C1-C1, C2-C3, C4-C4, C5-C ... 10 Alkyl, halogen, C6-C 10 Aromatic rings, C1-C6 alkoxy groups, 3-12 membered cycloalkane rings, -OC p H 2p -OC q H 2q+1 Nitro, oxo (=O), hydroxyl, carboxyl, -COOC1~C6 alkyl, -O-benzene ring, wherein each p is independently 1, 2 or 3, and each q is independently 1, 2 or 3.
[0027] In another preferred embodiment, the pharmaceutically acceptable salt is a salt obtained by reacting a compound of Formula I with an inorganic base, selected from: lithium salts, potassium salts, sodium salts, calcium salts, magnesium salts, copper salts, iron salts, ferrous salts, zinc salts, aluminum salts, ammonium salts, manganese salts, and manganese salts; or
[0028] The pharmaceutically acceptable salt is a salt obtained by reacting a compound with the structure shown in Formula I with an organic base compound, wherein the organic base is selected from the group consisting of: NH3, arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, aminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucosamine, histidine, hydroxycobalamin, isopropylamine, lysine, methylglucosamine, morpholine, piperazine, piperidine, polyamine resin, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, aminobutanetriol, and imidazole.
[0029] In another preferred embodiment, the compound is any of the compounds prepared in the examples.
[0030] A second aspect of the present invention provides a method for preparing the compound described in the first aspect, comprising the following steps:
[0031]
[0032] Using compounds of formula S1, S2, and S3 as starting materials, a compound having the structure shown in formula P1 was obtained by reaction.
[0033] The definitions of R1, R2, R3, L1, L2, L4, L5, Y, n1, n2, ring A, and B are as shown above;
[0034] L3 is O;
[0035] Each X1 is independently dimethylamino, ethylamino, or diisopropylamino;
[0036] X2 can be cyanoethyl, allyl, tert-butyl, or benzyl.
[0037] A third aspect of the present invention provides a method for preparing the compound described in the first aspect, comprising the following steps:
[0038]
[0039] Using compounds of formula S1, S3, and S4 as starting materials, a compound having the structure shown in formula P1 is obtained by reaction, wherein the definitions of R1, R2, R3, L1, L2, L4, L5, Y, n1, n2, ring A, and ring B are as shown above.
[0040] L3 is O or CH2; each X is independently F, Cl, Br or I.
[0041] A fourth aspect of the present invention provides a method for preparing the compound described in the first aspect, comprising the following steps:
[0042]
[0043] Using compounds of formula S1 and S5 as starting materials, a compound having the structure shown in formula P1 was obtained by reaction.
[0044] The definitions of R1, R2, R3, L1, L2, L4, L5, Y, n1, n2, ring A, and B are as shown above;
[0045] L3 is either O or CH2;
[0046] Each X is independently F, Cl, Br, or I.
[0047] A fifth aspect of the present invention provides a pharmaceutical composition comprising:
[0048] The compound represented by general formula (I) as described in the first aspect, or its enantiomers, diastereomers, racemates, or pharmaceutically acceptable salts thereof; and a pharmaceutically acceptable carrier.
[0049] A sixth aspect of the invention provides use of the compound described in the first aspect or its enantiomers, diastereomers, racemates or pharmaceutically acceptable salts thereof, or the pharmaceutical composition described in the fifth aspect, wherein the use is as follows:
[0050] (i) Used in the preparation of GPR84 antagonists;
[0051] (ii) Used as a GPR84 antagonist;
[0052] (iii) Drugs for the preparation of treatments for diseases caused by high expression or excessive excitability of the GPR84 receptor.
[0053] In another preferred embodiment, the disease is multiple sclerosis, inflammatory bowel disease, fibrosis, neurodegenerative disease, or arthritis.
[0054] In a seventh aspect, the present invention provides a method for treating diseases caused by high expression or excessive excitability of the GPR84 receptor by administering the compound of the present invention or a pharmaceutically acceptable salt to a patient in need.
[0055] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as are familiar to those skilled in the art. Furthermore, any methods and materials similar to or equivalent to those described herein may be applied to the methods of this invention. The preferred embodiments and materials described herein are for illustrative purposes only.
[0056] It should be understood that, within the scope of this invention, the above-described technical features of this invention and the technical features specifically described below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be described in detail here. Attached Figure Description
[0057] Figure 1 The tissue distribution of compounds XYF573c and LSX472a in ICR mice is shown. Detailed Implementation
[0058] The inventors of this application, through extensive and in-depth research, have developed a novel GPR84 antagonist. One ester group of the phosphodiester is a tricyclic fragment, while the other ester group is derived into various structural types, such as (cyclo)alkyl or substituted (cyclo)alkyl, aryl or substituted aryl, bile acid derivatives, etc. The compound of this application can competitively inhibit the activation of the receptor induced by GPR84 agonists, and can be used to prepare drugs for treating diseases caused by high expression or excessive excitability of the GPR84 receptor, including multiple sclerosis, inflammatory bowel disease, fibrosis, and arthritis. Furthermore, this asymmetric structural modification overcomes the structural characteristics of existing symmetric phosphodiester GPR84 antagonists, reducing the compound's CLogP while maintaining GPR84 antagonistic activity, resulting in better oral absorption and organ distribution characteristics, which is beneficial for developing drugs to treat organ fibrosis, arthritis, multiple sclerosis, and inflammatory bowel disease. Based on this, the present invention was completed.
[0059] the term
[0060] In this invention, C6-C 10 C3-C6 refers to having 6-10 carbon atoms, while C3-C6 refers to having 3-6 carbon atoms, and so on.
[0061] In this invention, unless otherwise stated, the terms aromatic ring, cycloalkane ring, alkyl, alkenyl, alkynyl, etc., have the same meaning as those skilled in the art. For example, alkyl refers to a saturated linear or branched hydrocarbon group; for example, -CH3 or -CH(CH3)2; alkylene refers to the portion of a saturated hydrocarbon group after formally eliminating two monovalent hydrogens, including but not limited to methylene (-CH2-), ethylene (-CH2CH2-), etc. Alkoxy refers to -O-(alkyl), including but not limited to -OCH3, -OCH2CH3, etc. Cycloalkane ring and cycloalkyl refer to saturated cyclic hydrocarbon groups, such as cyclohexyl. Heterocyclic alkyl and heterocyclic alkane rings refer to saturated cyclic hydrocarbon groups containing at least one (e.g., 1, 2, 3, or 4) heteroatoms (selected from: N, O, or S). Heteroaromatic ring and heteroaryl refer to aromatic rings containing at least one (e.g., 1, 2, 3, or 4) heteroatoms (selected from: N, O, or S).
[0062] Unless otherwise stated, the terms aromatic rings, heteroaromatic rings, cycloalkane rings, alkyl groups, alkylene groups, alkoxy groups, cycloalkyl groups, heterocycloalkyl groups, etc., as used herein include both substituted and unsubstituted groups. Possible substituents include, but are not limited to, C1-C1 substituents. 10 Alkyl, C2-C 10 alkenyl, C2-C 10 alkynyl group, C3-C 20 cycloalkyl, C3-C 20 Cycloalkenyl, C1-C 20 Heterocyclic alkyl, C1-C 20Heterocyclic alkenyl, C1-C 10 Alkyl, aryl, aryloxy, heteroaryl, heteroaryloxy, amino, hydroxyl, halogen, mercapto, cyano, nitro, carboxyl, and carboxylic acid ester groups, etc.
[0063] GPR84 antagonist
[0064] The GPR84 antagonist provided by this invention is a compound having the structure of Formula I shown above.
[0065] This invention also provides pharmaceutically acceptable salts, including salts obtained by reacting compounds of formula I with inorganic or organic bases. Salts derived from inorganic bases include, but are not limited to, aluminum salts, ammonium salts, calcium salts, copper salts, iron salts, ferrous salts, lithium salts, magnesium salts, manganese salts, manganese salts, potassium salts, sodium salts, zinc salts, etc. Ammonium salts, calcium salts, magnesium salts, potassium salts, and sodium salts are particularly preferred. Salts derived from pharmaceutically acceptable organic non-toxic bases, including, but not limited to, salts of primary, secondary, and tertiary amines. Substituted amines include naturally occurring substituted amines, cyclic amines, and basic ion exchange resins such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, aminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucosamine, histidine, hydroxycobalamin, isopropylamine, lysine, methylglucosamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, aminobutanetriol, imidazole, etc.
[0066] The main advantages of this invention are:
[0067] The inventors have developed a novel GPR84 antagonist with one ester group of the phosphate diester being a tricyclic fragment, while the other ester group is derived into various structural types, such as (cyclo)alkyl or substituted (cyclo)alkyl, aryl or substituted aryl, and bile acid derivatives. This modification helps to expand the chemical cosmology of GPR84 antagonists, reduce CLogP, and improve their oral absorption and organ distribution characteristics, thereby contributing to the treatment of GPR84-related diseases.
[0068] In summary, the compounds provided by this invention can better maintain their antagonistic activity against GPR84, while exhibiting better oral absorption and more specific target tissue distribution characteristics, thus showing better development prospects.
[0069] Preparation method
[0070] Compound I can be achieved through any of the following routes one through five:
[0071] Route 1:
[0072]
[0073] The first step reaction is carried out in dichloromethane or acetonitrile; the activating agent used is 4,5-dicyanimidazolium, diisopropylaminotetrazolium salt, or N-methylimidazolium; the reaction temperature is 20℃~60℃; the reaction time is approximately 1~24h; after the reaction is completed, the mixture is neutralized with saturated NaHCO3 or Na2CO3 solution, and extracted with solvents such as AcOEt, Et2O, CH2Cl2, and CHCl3. The concentrate is purified by column chromatography. The second step reaction is carried out in dichloromethane or N,N-dimethylformamide, using tetrazolium as the activating agent. The reaction time is approximately 1~24h, followed by oxidation with an oxidizing agent, such as tert-butyl hydroperoxide or m-chloroperoxybenzoic acid, for approximately 0.3~2h. The reaction is quenched with saturated Na2SO3, and extracted with solvents such as AcOEt, Et2O, CH2Cl2, and CHCl3. The concentrate is purified by column chromatography. The third step of the reaction takes place in dichloromethane. Depending on the protecting group X2, the conditions used are either catalytic hydrogenation or alkaline catalysis. The catalyst used for catalytic hydrogenation is Pd / C or Pd(OH). 2 / Add hydrogen gas at atmospheric pressure; the base used for alkaline catalysis is triethylamine or 1,8-diazabicycloundec-7-ene (DBU), and the reaction time is about 0.3 to 1 hour. After the reaction is completed, filter to remove insoluble matter, add dilute hydrochloric acid for neutralization, and extract with solvents such as AcOEt, Et2O, CH2Cl2, and CHCl3. The concentrate is subjected to column chromatography to obtain the target product, and the obtained product is confirmed by NMR and other methods.
[0074] The definitions of R1, R2, R3, L1, L2, L4, L5, Y, n1, n2, ring A, and B are as shown above; L3 is O; each X1 is independently dimethylamino, ethylamino, or diisopropylamino; X2 is cyanoethyl, allyl, tert-butyl, or benzyl.
[0075] Route 2:
[0076]
[0077] The reaction was carried out in pyridine at a temperature of 60℃–100℃ for approximately 1–24 hours. After the reaction was completed, the mixture was cooled to room temperature, and S3 was added. The reaction was then carried out at 60℃–100℃ for 1–24 hours. After the reaction was completed, the mixture was quenched with water and extracted with solvents such as AcOEt, Et2O, CH2Cl2, and CHCl3. The concentrate was purified by column chromatography to obtain the target product, which was then confirmed by NMR and other methods. The definitions of R1, R2, R3, L1, L2, L4, L5, Y, n1, n2, ring A, and ring B are as previously stated; L3 represents O, S, NH, or CH2; and each X is independently F, Cl, Br, or I.
[0078] Route 3:
[0079]
[0080] The reaction was carried out in pyridine; the reaction temperature was 60℃~100℃; the reaction time was about 1~24h; after the reaction was completed, it was quenched with H2O, extracted with solvents such as AcOEt, Et2O, CH2Cl2, CHCl3, etc., washed with saturated brine, dried, and the solvent was removed under low temperature and reduced pressure. The concentrate was subjected to column chromatography to obtain the target product, and the obtained product was confirmed by NMR and other methods.
[0081] The definitions of R1, R2, R3, L1, L2, L4, L5, Y, n1, n2, ring A, and B are as shown above; L3 is O or CH2; each X is independently F, Cl, Br, or I.
[0082] Route 4:
[0083]
[0084] Raw material P1 was dissolved in ethyl acetate, washed twice with an aqueous solution of alkali (the conjugate base of M, the hydroxide of M, or the carbonate of M), the aqueous layer was back-extracted with ethyl acetate, the ethyl acetate layer was concentrated, and the crude product was precipitated by silica gel column chromatography to obtain product P2.
[0085] M is a cation of the following metals: Li, Na, K, Ca, Mg, Cu, Fe, Zn, Al, Mn, or a conjugate acid of the following bases: NH3, arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, aminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucosamine, histidine, hydroxycobalamin, isopropylamine, lysine, methylglucosamine, morpholine, piperazine, piperidine, polyamine resin, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, aminobutanetriol, imidazole, etc.
[0086] The definitions of R1, R2, R3, L1, L2, L4, L5, Y, n1, n2, ring A, and B are as shown above;
[0087] L3 is either O or CH2.
[0088] Route 5:
[0089]
[0090] The reaction was carried out in N,N-dimethylformamide (DMF) using 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC·HCl) and dimethylaminopyridine (DMAP) as activators. The base used was triethylamine or N,N-diisopropylethylamine. The reaction time was approximately 6–24 h at room temperature. After the reaction was completed, the solvent was removed under reduced pressure at low temperature. The product was extracted with ethyl acetate, back-extracted three times with water, washed with saturated brine, concentrated, and then subjected to column chromatography to obtain the target product. The product was confirmed by NMR and other methods.
[0091] The definitions of R1, R2, R3, R4, L1, L2, L4, Y, n1, n2, ring A, and B are as shown above;
[0092] L5 is independently non-negative and -(CH2). m -、-(CH2) m -CH = CH-, -(CH2) m -C≡C-、-(C2H4O) m -、-(CH2) m -NH-, -(CH2) m -O-, where each m is an independent integer between 0 and 10;
[0093] R4 is C1-C 10 Substituted or unsubstituted alkyl groups, substituted or unsubstituted C6-C 10 Aromatic rings, C3-C 10 Cycloalkanes, C3-C 10 Heterocyclic alkane rings, C3-C 10 The following are listed: heteroaryl rings, cholic acids, lithocholic acids, deoxycholic acids, isolithocholic acids, isodeoxycholic acids, chenodeoxycholic acids, ursodeoxycholic acids, α-mouse cholic acid, β-mouse cholic acid, γ-mouse cholic acid, ω-mouse cholic acid; the substitution refers to having one or more substituents selected from the group consisting of: C1-C6 alkyl, C1-C6 alkoxy, halogen, hydroxyl.
[0094] L3 is either O or CH2.
[0095] use
[0096] Compound I, as an antagonist of GPR84, can competitively inhibit the activation of the receptor caused by GPR84 agonists. It can be used to prepare drugs for treating diseases caused by high expression or excessive excitability of the GPR84 receptor, including multiple sclerosis, inflammatory bowel disease, organ fibrosis, arthritis, etc.
[0097] Pharmaceutical Composition
[0098] The pharmaceutical compositions of the present invention contain a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, and contain one or more pharmaceutically acceptable carriers.
[0099] "Pharmaceutical-grade carrier," "pharmaceutically acceptable carrier," or "pharmaceutically usable carrier" refers to one or more compatible solid or liquid fillers or gel substances that are suitable for human use and must have sufficient purity and sufficiently low toxicity. "Compatibility" here means that the components in the composition can interact with and be mixed with the active ingredient of the invention (the compound of Formula I or a pharmaceutically acceptable salt thereof) without significantly reducing the efficacy of the active ingredient. Examples of pharmaceutically-grade carriers include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifiers (such as... Wetting agents (such as sodium dodecyl sulfate), colorants, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.
[0100] The compounds and pharmaceutical compositions of the present invention can be in various forms, and can be administered orally or non-orally as injections, such as capsules, tablets, granules, solutions, powders, granules, or syrups. The compounds and pharmaceutical compositions of the present invention can be contained in suitable solid or liquid carriers and suitable sterile instruments for injection or infusion. The above-mentioned formulations can be prepared using conventional pharmaceutical methods.
[0101] The compounds and pharmaceutical compositions of the present invention can be used clinically in mammals, including humans and animals, and can be administered via oral, nasal, or gastrointestinal routes. The most preferred route of administration is oral.
[0102] The features mentioned above in this invention, or the features mentioned in the embodiments, can be combined in any way. All features disclosed in this specification can be used in any compositional form, and each feature disclosed in the specification can be replaced by any alternative feature that provides the same, equivalent, or similar purpose. Therefore, unless otherwise specified, the disclosed features are merely general examples of equivalent or similar features.
[0103] The present invention will be further illustrated below with reference to specific embodiments. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of the invention. Experimental methods in the following embodiments, unless otherwise specified, are generally performed under conventional conditions as described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or as recommended by the manufacturer. Unless otherwise stated, percentages and parts are weight percentages and parts by weight.
[0104] In the following examples, NMR was measured using a Bruker AVANCE III 400M instrument. NMR calibration values were: δH 7.26 ppm (CDCl3), 2.50 ppm (DMSO-d6), and 3.15 ppm (CD3OD). Reagents were mainly provided by Shanghai Chemical Reagent Company. TLC silica gel plates were manufactured by Shandong Yantai Huiyou Silica Gel Development Co., Ltd., model HSGF 254. Normal-phase column silica gel used for compound purification was manufactured by Shandong Qingdao Marine Chemical Plant Branch, model ZCX-11, 200-300 mesh.
[0105] Example 1
[0106] Preparation of compound LSX448
[0107]
[0108] Synthesis of intermediate G1M. Starting material G1 (200 mg, 0.78 mmol) and 4,5-dicyanimidazole (184 mg, 1.56 mmol) were dissolved in dry dichloromethane. Under argon protection at 20 °C, bis(diisopropylamino)(2-cyanoethoxy)phosphine (0.495 ml, 1.56 mmol) was added dropwise. After reacting at 20 °C for 5 h, saturated NaHCO3 was added to adjust the pH to 7. The mixture was concentrated, extracted with dichloromethane, back-extracted three times with water, washed with saturated brine, dried over anhydrous Na2SO4, filtered, concentrated, and subjected to silica gel column chromatography (PE:AcOEt = 15:1–10:1) to obtain intermediate G1M (280 mg, 78%, colorless liquid).
[0109]
[0110] Synthesis of compound LSX448. Intermediate G1M was dissolved in dry dichloromethane, and tetrazolium (43 mg, 0.63 mmol) and G2 (0.097 mL, 0.63 mmol) were added. The reaction was carried out for 4 h, followed by the addition of peroxytert-butanol (70% in water) (0.094 mL, 0.63 mmol), and the reaction was carried out for 1 h. The mixture was neutralized with saturated sodium sulfite solution, extracted with ethyl acetate, back-extracted three times with water, washed with saturated brine, dried over anhydrous Na2SO4, filtered, concentrated, and subjected to silica gel column chromatography (PE:AcOEt = 10:1 to 2:1) to obtain intermediate G1N. G1N was dissolved again in dry dichloromethane, and 1,8-diazabicycloundec-7-ene (0.094 mL, 0.63 mmol) was added. The reaction was carried out for 30 mins, and 1 mol / L [concentration of 1 mol / L ethyl acetate] was added. The pH was adjusted to 7 with HCl, extracted with ethyl acetate, back-extracted three times with water, washed with saturated brine, dried over anhydrous Na2SO4, filtered, concentrated, and subjected to silica gel column chromatography (DCM:MeOH = 15:1 to 10:1). The solvent was evaporated to obtain the target compound LSX448 (35 mg, 10%, white solid). 1 H NMR(d6-DMSO,400MHz): δ7.46(d,J=7.2Hz,1H),7.31-7.20(m,6H),7.08(d,J=7.2Hz,1 H), 3.87 (m, 2H), 3.83 (s, 3H), 1.45 (m, 2H), 1.24-1.14 (m, 10H), 0.78 (t, J = 7.6Hz, 3H).
[0111] The following compounds were synthesized using the same method.
[0112]
[0113]
[0114]
[0115]
[0116]
[0117]
[0118]
[0119]
[0120]
[0121]
[0122] Example 2
[0123] Preparation of compound LSX442
[0124]
[0125] The starting material G1 (200 mg, 0.78 mmol) was dissolved in dry pyridine (5 mL). Under argon protection, redistilled POCl3 (0.078 mL, 0.86 mmol) was added dropwise. The reaction was carried out overnight at 80 °C. The next day, after cooling to room temperature, G3 (290 mg, 2.34 mmol) was added dropwise to the system. After the addition was complete, the system was heated to 80 °C and reacted for 6 h. After returning to room temperature, the reaction was quenched with water. The pH was adjusted to 7 with 1 mol / L hydrochloric acid. The mixture was extracted with ethyl acetate, back-extracted three times with water, washed with saturated brine, dried over anhydrous Na2SO4, filtered, concentrated, and subjected to silica gel column chromatography (DCM:MeOH = 15:1 to 10:1). The solvent was evaporated to obtain the target compound LSX442 (40 mg, 12%, white solid). 1 H NMR (400MHz, DMSO-d6) δ7.46 (d, J = 7.2 Hz, 1H), 7.29-7.04 (m, 9H), 6.78 (d, J = 8.4 Hz, 2H), 3.83 (s, 3H), 3.67 (s, 3H).
[0126] The following compounds were synthesized using the same method.
[0127]
[0128]
[0129] Example 3
[0130] Preparation of compound LSX432
[0131]
[0132] The starting material G1 (200 mg, 0.78 mmol) was dissolved in dry pyridine (5 mL), and G5 (0.480 mL, 2.34 mmol) was added dropwise under argon protection. The reaction was carried out overnight at 80 °C, and the reaction was quenched with water after returning to room temperature. The pH was adjusted to 7 with 1 mol / L hydrochloric acid, extracted with ethyl acetate, back-extracted three times with water, washed with saturated brine, dried over anhydrous Na2SO4, filtered, concentrated, and subjected to silica gel column chromatography (DCM:MeOH = 15:1 to 10:1). The solvent was evaporated to obtain the target compound LSX432 (120 mg, 35%, white solid). 1H NMR(400MHz, DMSO-d6)δ7.43(d,J=7.2Hz,1H),7.39–7.10(m,6H),7.05(d,J=7.2 Hz,1H),3.83(s,3H),1.49–1.35(m,4H),1.30–1.03(m,10H),0.89–0.79(m,3H).
[0133] Example 4
[0134] Preparation of compound LSX419
[0135]
[0136] Intermediate G1M (368 mg, 0.78 mmol) was dissolved in dry dichloromethane, and peroxytert-butanol (70%, in water) (0.094 mL, 0.63 mmol) was added. The reaction was carried out for 1 h, neutralized with saturated sodium sulfite solution, extracted with ethyl acetate, back-extracted three times with water, washed with saturated brine, dried over anhydrous Na2SO4, filtered, concentrated, and subjected to silica gel column chromatography (PE:AcOEt = 10:1 to 2:1) to obtain intermediate G1N. Intermediate G1N was dissolved in dry dichloromethane, and 1,8-diazabicycloundec-7-ene (0.094 mL, 0.63 mmol) was added. The reaction was carried out for 30 min, and 1 mol / L [concentration of 1 mol / L ethyl acetate] was added. The pH was adjusted to 7 with HCl, extracted with ethyl acetate, back-extracted three times with water, washed with saturated brine, dried over anhydrous Na2SO4, filtered, concentrated, and subjected to silica gel column chromatography (DCM:MeOH = 15:1 to 10:1). The solvent was evaporated to obtain the target compound LSX419 (120 mg, 18%, white solid). 1 H NMR(400MHz,DMSO-d6)δ7.49(d,J=7.2Hz,1H),7.38–7.24(m,5H),7.20(dd,J=7.2,1.2Hz,1H), 7.13(dd,J=7.2,1.2Hz,1H),3.85(s,3H),3.44(dp,J=20.0,6.8Hz,2H),1.15(d,J=6.8Hz,12H).
[0137] Example 5
[0138] Preparation of compound LSX784
[0139]
[0140] Intermediate G1M (920 mg, 0.78 mmol) was dissolved in dry dichloromethane. Tetrazazole (107 mg, 1.575 mmol) and G6 (0.242 mL, 1.575 mmol) were added, and the reaction was carried out for 4 h. Peroxytert-butanol (70%, in water) (0.235 mL, 1.575 mmol) was added, and the reaction was carried out for 1 h. The mixture was neutralized with saturated sodium sulfite solution, extracted with ethyl acetate, back-extracted three times with water, washed with saturated brine, dried over anhydrous Na2SO4, filtered, concentrated, and subjected to silica gel column chromatography (PE:AcOEt = 10:1 to 2:1). The intermediate was dissolved in dry dichloromethane, and 1,8-diazabicycloundec-7-ene (0.235 mL, 1.575 mmol) was added. The reaction was carried out for 30 min, and 1 mol / L [concentration of 1 mol / L] ... The pH was adjusted to 7 with HCl, extracted with ethyl acetate, back-extracted three times with water, washed with saturated brine, dried over anhydrous Na₂SO₄, filtered, concentrated, and subjected to silica gel column chromatography (DCM:MeOH = 15:1–10:1). The solvent was evaporated to obtain an intermediate, which was dissolved in ethyl hydrochloride solution. The reaction was carried out at room temperature for 2 hours, and the solvent was removed under reduced pressure at low temperature. After vacuum drying, cholic acid (122 mg, 0.298 mmol), EDCI (86 mg, 0.448 mmol), and DMAP (109 mg, 0.892 mmol) were added. The reaction was carried out at room temperature for 2 days with N,N-dimethylformamide and triethylamine as solvents. The solvent was removed under reduced pressure after the reaction was carried out. The mixture was concentrated and subjected to silica gel column chromatography (DCM:MeOH:AcOH = 10:1:0.1–5:1:0.1) to obtain LSX784 (16 mg, 1.05%, white solid). 1 H NMR(400MHz,DMSO-d6)δ7.46(d,J=7.6Hz,1H),7.38–7.17(m,6H),7.13–7.06(m,1H),4.31 (d,J=4.4Hz,1H),4.16–4.06(m,1H),4.00(d,J=3.2Hz,1H),3.94–3.80(m,5H),3.80–3.74 (m,1H),3.67–3.55(m,1H),3.09(q,J=6.8Hz,2H),2.28–2.06(m,2H),2.07–1.91(m,1H),1 .86–1.70(m,4H),1.72–1.57(m,4H),1.49–1.09(m,15H),1.04–0.77(m,12H),0.59(s,3H).
[0141] Example 6
[0142] (1) Experimental Objective
[0143] The GPR84 antagonistic activity of the compounds of this invention was tested.
[0144] (2) Source of materials
[0145] The human GPR84 cell line was obtained by transfecting HEK293 cell line with plasmids encoding GPR84 and Gα16 proteins. Fluo-4 AM fluorescent dye was purchased from Invitrogen.
[0146] (3) Testing principle
[0147] Intracellular Ca 2+ Ions are a very important second messenger in the G protein-coupled receptor signaling pathway, and when they interact with Gα... 16 After protein-coupled GPR84 binds to its agonist, intracellular calcium... 2+ The ion concentration can be significantly increased. Fluo-4 is a type of Ca... 2+ Ion-specific fluorescent probes that can react with Ca 2+ Ions bind quantitatively and emit fluorescence. Therefore, fluorescence detection is used to detect the agonist or antagonist activity of compounds in 96-well or 384-well flat-bottom microplates.
[0148] Detection of receptor inhibitory effect of GPR84 antagonists: GPR84 cells were incubated with the fluorescent dye Fluo-4, and then incubated with different concentrations of antagonist compounds for a period of time to allow them to occupy the binding sites of the agonist and GPR84 (antagonist binding sites). A certain concentration of the agonist (6-n-octylaminouracil, 6-OAU) was then added to compete with the antagonist compounds for binding sites. Simultaneously, the cells were excited with a 485 nm light source, and changes in the dye fluorescence intensity caused by changes in intracellular calcium ion concentration were detected at 525 nm. The half-maximal inhibitory concentration (IC50) of the compounds was calculated using GraphPad PRISM software. 50 ).
[0149] (4) Experimental procedure
[0150] Prepare HBSS: 0.4 g / L KCl (5.4 mM), 0.12 g / L Na2HPO4·12H2O (0.3 mM), 0.06 g / L KH2PO4 (0.4 mM), 0.35 g / L NaHCO3 (4.2 mM), 0.14 g / L CaCl2 (1.3 mM), 0.10 g / L MgCl2·6H2O (0.5 mM), 0.05 g / L MgSO4 (0.6 mM), 8.0 g / L NaCl (137 mM). Weigh out all the above components and dissolve them in ultrapure water. Adjust the pH to 7.4 with hydrochloric acid or NaOH solution, filter, and store at 4°C for one month.
[0151] Preparation of calcium flux buffer: First, prepare 560 mM D-glucose (100X) water-soluble stock solution and 250 mM 1,2-diphenyl-4-(2-phenylthionyl)ethyl-3,5-pyrazolidinedione (1000X) stock solution. Then, add BSA (0.5 g), 560 mM D-glucose stock solution (1 mL), and 250 mM 1,2-diphenyl-4-(2-phenylthionyl)ethyl-3,5-pyrazolidinedione stock solution (100 μ L) to 100 mL of HBSS to achieve final concentrations of 0.5% BSA, 5.6 mM D-glucose, and 250 μ M 1,2-diphenyl-4-(2-phenylthionyl)ethyl-3,5-pyrazolidinedione. Mix well and use immediately.
[0152] Dye preparation: Mix 1 μL of DMSO solution of 2 mM Fluo-4 AM (1000X, purchased from Invitrogen) with 10 μL of PBS solution of 3% Cremophor EL (100X, purchased from Sigma-Aldrich), and then add 1 mL of calcium flux buffer and mix well.
[0153] Cells were packed at 4 × 10 4 Seeds were planted at a density of 1 sample per well in 96-well plates. After 24 h of incubation, the culture medium was removed, and 40 μL of Fluo-4AM fluorescent dye was added to each well. The plates were incubated at 37 °C for 40 min. After the dye was removed, 50 μL of the test compound was added, and the plates were incubated at room temperature for 10 min. Then, 25 μL of 6-OAU (the effective concentration after dilution is 1 / 3 of the EC50 of this agonist) was added using a Flex Station III microplate reader. 80 The cells were stimulated (left and right) and the changes in the fluorescence intensity of the Fluo-4AM dye caused by the changes in intracellular calcium ion flow were read in real time (excitation wavelength 485nm, detection wavelength 525nm).
[0154] (5) Experimental Results
[0155] Table 1. IC50 of compounds 50 With LogP
[0156] compound <![CDATA[IC 50 a ]]> <![CDATA[CLogP b ]]> <![CDATA[ALogP c ]]> compound <![CDATA[IC 50 ]]> CLogP ALogP XYF573c *** 6.419 6.8 LSX470b ** 5.346 5.076 LSX350 * 1.647 2.818 LSX472a *** 5.51 5.152 LSX406 * 2.095 2.6 LSX472b *** 5.51 5.152 LSX406-2 * 3.763 4.6 LSX472j *** 5.51 5.287 LSX412 * 3.421 4.4 LSX474-2 ** 5.524 5.843
[0157] LSX419 ** 5.476 3.83 LSX474-3 ** 5.754 5.863 LSX420 * 1.279 2.66 LSX474a *** 5.644 5.956 LSX420-3 ** 4.292 5.06 LSX474b *** 5.644 5.956 LSX426j * 5.317 4.75 LSX476a *** 6.326 5.833 LSX430 * 3.564 3.601 LSX476b *** 6.326 5.833 LSX430-2 ** 3.953 4.42 LSX472c *** 5.51 5.152 LSX431 * 6.725 3.752 LSX472d *** 5.51 5.152 LSX432 ** 5.715 5.632 LSX472e *** 5.51 5.287 LSX432-2a * 4.197 4.996 LSX472f *** 5.51 5.287 LSX432-2b * 4.197 4.929 LSX472g *** 5.51 5.152 LSX432-2c * 4.197 4.929 LSX472h ** 5.51 5.152 LSX432-3 * 4.237 5.133 LSX476c ** 6.326 5.833 LSX434 ** 4.821 5.516 LSX476d ** 6.326 5.833 LSX434-2 * 3.133 3.18 LSX476e ** 6.326 5.968 LSX440 * 3.744 4.723 LSX476f ** 6.326 5.968 LSX442 ** 3.34 4.38 LSX476g *** 6.326 5.833 LSX442a ** 5.557 5.17 LSX476h ** 6.326 5.833 LSX442j * 5.557 5.3 LSX476j ** 6.326 5.968 LSX444 ** 4.392 5.785 LSX480 ** 4.847 5.724 LSX444-2 ** 4.572 4.683 LSX482a ** 6.036 6.706 LSX446 ** 4.866 5.527 LSX482b *** 6.036 6.706 LSX446-2 * 4.716 5.315 LSX482c ** 6.036 6.706 LSX447 ** 7.257 5.235 LSX491a ** 4.284 5.144 LSX448 ** 5.35 5.972 LSX492 * 3.78 4.92 LSX452 ** 6.166 6.653 LSX496 * 6.275 6.783 LSX454 * 4.848 5.589 LSX498 ** 5.344 5.374 LSX456j * 5.236 4.73 LSX504 * 5.519 5.96 LSX457 * 3.164 4.289 LSX526a ** 6.619 7.29 LSX460 ** 5.125 5.704 LSX526j *** 6.619 7.42
[0158] LSX460a ** 5.756 5.37 LSX527 ** 5.203 6.905 LSX460j ** 5.756 5.51 LSX548 * 8.705 8.080 LSX462-3 ** 5.879 6.428 LSX552 ** 8.651 9.017 LSX462a ** 4.595 5.303 LSX602 *** 4.201 4.5 LSX462b ** 4.595 5.3 LSX644 * 4.231 3.56 LSX466 * 4.623 5.686 LSX694 ** – 7.657 LSX468a ** 5.347 6.075 LSX710 ** – 6.488 LSX468b ** 5.347 6.075 LSX726 * – 5.386 LSX470a ** 4.306 4.961 LSX784 * – 5.191
[0159] a IC 50 :*1–10μM; **0.1–1μM; ***<0.1μM
[0160] bThe CLogP values were calculated using ChemBioDraw software (version Ultra 12.0) from CambridgeSoft, USA. All structures used in the calculations were in the free acid form of the compounds.
[0161] c ALogP value is determined by the United States. The calculations were performed using the company's Maestro software (version 11.2). All compounds were calculated based on their ionization state at pH 7. The ALogP and CLogP data for compound LSX431 differed significantly due to the protonation of its phosphoramide nitrogen atom.
[0162] (6) Results Analysis
[0163] Table 1 shows that the compound IC of the present invention... 50 The values were all less than 10 μM, and the IC50 values for some compounds were also low. 50 The values range from 0.1 to 1 μM, and the IC50 values for some compounds are... 50 The values are even less than 100 nM, indicating that the compounds of the present invention can be used as GPR84 antagonists. Furthermore, compared to the existing compound XYF573c (IC), the values are significantly lower. 50 =26.2 nM, CLogP=6.419, ALogP=6.80), of which 30 compounds had CLogP between 5 and 6, 37 compounds had CLogP < 5, 47 compounds had ALogP between 5 and 6, and 26 compounds had ALogP < 5, which are significantly lower than the CLogP and ALogP of XYF573c.
[0164] Example 7
[0165] (1) Experimental Objective
[0166] The tissue distribution experiments of compounds XYF573c and LSX472a of this invention in ICR mice were conducted to compare their distribution in plasma and organs with their oral exposure (AUC). 0-8h ).
[0167] (2) Source of materials
[0168] ICR mice were purchased from the Shanghai Experimental Animal Research Center.
[0169] (3) Testing principle
[0170] The concentrations of the compound in the plasma and organs of ICR mice were determined by LC-MS.
[0171] (4) Experimental procedure
[0172] Mice were fasted for more than 12 hours during the experiment, but given free access to water. Food was provided 2 hours after drug administration.
[0173] Both compounds XYF573c and LSX472a were administered orally at a dose of 5 mg / kg in a solvent of DMSO / 0.5% HPMC = 5 / 95, v / v, N = 3.
[0174] 0.5h, 2h and 8h after oral administration, approximately 20 μL of mouse cardiac blood, portal vein plasma or 20 mg of liver, lung and ileum tissue were collected into clean centrifuge tubes, 200 μL of MeOH / ACN (50 / 50, v / v) was added, and the mixture was vortexed for 1 minute. The mixture was centrifuged at 15000 rpm for 5 minutes, and 20 μL of the supernatant was mixed with 20 μL of ACN / water (1 / 1, v / v) and quantitatively analyzed by LC-MS.
[0175] AUC 0-8h The values were calculated using the trapezoidal method based on the concentrations of the compound at 0.5h, 2h, and 8h.
[0176] (5) Experimental Results
[0177] The reduction in cLogP is crucial for improving the oral absorption of compounds. The cLogP of the compound LSX472a of this invention is 5.51, a decrease of 0.9 compared to XYF573c. This change is also reflected in the oral exposure (Plasma AUC) of LSX472a. 0-8h It is 13 times better than XYF573c. Figure 1 (See Table 1). Furthermore, LSX472a showed significantly increased exposure in the intestine (e.g., ileum) compared to XYF573c. Therefore, this invention extends the structure of GPR84 antagonists, improves the drug-like properties of such compounds, increases their oral absorption, and also helps improve the target tissue distribution of the compounds.
[0178] Table 1. Oral exposure of compounds XYF573c and LSX472a
[0179]
[0180] All documents mentioned in this invention are incorporated herein by reference as if each document were individually incorporated by reference. Furthermore, it should be understood that after reading the foregoing teachings of this invention, those skilled in the art can make various alterations or modifications to this invention, and these equivalent forms also fall within the scope defined by the appended claims.
Claims
1. A compound of general formula (I) or a pharmaceutically acceptable salt thereof, (I) In the formula, Y represents O or S; Z is H; L1 is either O or S; L2 is CH; Ring A and ring B are benzene rings; n1 and n2 are each independently 0, 1, or 2; R1 and R2 are each independently selected from: F, Cl, Br, I, substituted or unsubstituted -C. r H 2r -L7-C s H 2s+1 The above substitution refers to having one or more substituents selected from the group consisting of: halogen; L7 is O, r is 0, and s is 1, 2, 3, 4, 5, or 6; L3 is O; L4 represents 0, none, or -O (C1~C). 10 Alkylene)-, -O(C1~C 10 Alkylene)NH-, -O(C1~C 10 Alkylene) O-, -NH- or C1~C 10 Alkylene; R3 is selected from: substituted or unsubstituted C1~C 10 Alkyl, unsubstituted C2~C 10 Alkenyl, unsubstituted C2~C 10 Alkyne group, substituted or unsubstituted 3-12 membered cycloalkanes, substituted or unsubstituted C6-C 14 Aromatic ring, substituted or unsubstituted amino group, substituted or unsubstituted 4-10 membered heterocyclic alkane ring, cholic acid, lithocholic acid, deoxycholic acid, isolithocholic acid, isodeoxycholic acid, chenodeoxycholic acid, ursodeoxycholic acid, α-mouse cholic acid, β-mouse cholic acid, γ-mouse cholic acid, ω-mouse cholic acid; the above substitution refers to having 1, 2, 3 or 4 substituents selected from the group consisting of: amino, C1~C1, C2, C3, C4, C5, C6, C7, C8, C9 ... 10 Alkyl, halogen, C6-C 10 Aromatic rings, C1-C6 alkoxy groups, 3-12 membered cycloalkane rings, -OC p H 2p -OC q H 2q+1 Nitro, oxo (=O), hydroxyl, carboxyl, -C(O)OC1~C6 alkyl, -O-C6-C 10 Aromatic rings, -NH-(4-10-membered heteroaryl rings), -NH-(4-10-membered heteroaryl rings)-CONH2, among which, p is 1, 2, 3, or 4, and q is 1, 2, 3, or 4; The heteroatoms of the aforementioned heterocyclic alkane rings are selected from N, O, or S; the heteroatoms of the heteroaromatic rings are selected from N, O, or S.
2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, characterized in that, L1 is S; L2 is CH.
3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, characterized in that, n1 is 0, 1, or 2; R1 is F, Cl, Br, I, methoxy, ethoxy, n-propoxy, isopropoxy, or trifluoromethoxy.
4. The compound of claim 1 or a pharmaceutically acceptable salt thereof, characterized in that, n2 is 0, 1, or 2; R2 is F, Cl, Br, I, methoxy, ethoxy, n-propoxy, isopropoxy, or trifluoromethoxy.
5. The compound of claim 1 or a pharmaceutically acceptable salt thereof, characterized in that, L4 can be O, none, -NH-, -OCH2NH-, -OCH2CH2NH-, -OCH2CH2CH2NH-, -CH2-, or -CH2CH2-.
6. The compound of claim 1 or a pharmaceutically acceptable salt thereof, characterized in that, R3 represents substituted or unsubstituted C1~C. 10 Alkyl, unsubstituted C2~C 10 Alkenyl, unsubstituted C2~C 10 Alkyne group, substituted or unsubstituted 3-12 membered cycloalkanes, substituted or unsubstituted C6-C 14 Aromatic ring, substituted or unsubstituted amino group, substituted or unsubstituted 4-10 membered heterocyclic alkane ring, cholic acid, lithocholic acid, deoxycholic acid, isolithocholic acid, isodeoxycholic acid, chenodeoxycholic acid, ursodeoxycholic acid, α-mouse cholic acid, β-mouse cholic acid, γ-mouse cholic acid, ω-mouse cholic acid; the above substitution refers to having 1, 2, 3 or 4 substituents selected from the group consisting of: amino, C1~C1, C2, C3, C4, C5, C6, C7, C8, C9 ... 10 Alkyl, halogen, C6-C 10 Aromatic rings, C1-C6 alkoxy groups, 3-12 membered cycloalkane rings, -OC p H 2p -OC q H 2q+1 Nitro, oxo (=O), hydroxyl, carboxyl, -COOC1~C6 alkyl, -O-benzene ring, where p is 1, 2 or 3, and q is 1, 2 or 3.
7. The compound of claim 1 or a pharmaceutically acceptable salt thereof, characterized in that, The pharmaceutically acceptable salt is a salt obtained by reacting a compound of general formula (I) with an inorganic base, selected from: lithium salts, potassium salts, sodium salts, calcium salts, magnesium salts, copper salts, iron salts, ferrous salts, zinc salts, aluminum salts, ammonium salts, manganese salts, and manganese salts; or The pharmaceutically acceptable salt is the salt obtained by reacting a compound of general formula (I) with an organic base selected from the group consisting of: NH3, arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, aminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucosamine, histidine, hydroxycobalamin, isopropylamine, lysine, methylglucosamine, morpholine, piperazine, piperidine, polyamine resin, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, aminobutanetriol, and imidazole.
8. A compound or a pharmaceutically acceptable salt thereof, characterized in that, The compound is selected from:
9. The compound of claim 8 or a pharmaceutically acceptable salt thereof, characterized in that, The pharmaceutically acceptable salt is a salt obtained by reacting a compound with an inorganic base, selected from: lithium salts, potassium salts, sodium salts, calcium salts, magnesium salts, copper salts, iron salts, ferrous salts, zinc salts, aluminum salts, ammonium salts, manganese salts, and manganese salts; or The pharmaceutically acceptable salt is a salt obtained by reacting a compound with an organic base selected from the group consisting of: NH3, arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, aminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucosamine, histidine, hydroxycobalamin, isopropylamine, lysine, methylglucosamine, morpholine, piperazine, piperidine, polyamine resin, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, aminobutanetriol, and imidazole.
10. The method for preparing the compound according to claim 1, characterized in that, The compound has the structure shown in formula P1, and the method includes the following steps: Using compounds of formula S1, S2, and S3 as starting materials, a compound having the structure shown in formula P1 was obtained by reaction. The definitions of R1, R2, R3, L1, L2, L4, Y, n1, n2, ring A, and ring B are as described in claim 1; L3 is O; Each X1 is independently dimethylamino, ethylamino, or diisopropylamino; X2 can be cyanoethyl, allyl, tert-butyl, or benzyl.
11. The method for preparing the compound according to claim 1, characterized in that, The compound has the structure shown in formula P1, and the method includes the following steps: Using compounds of formula S1, S3, and S4 as starting materials, a compound having the structure shown in formula P1 was obtained by reaction. The definitions of R1, R2, R3, L1, L2, L4, Y, n1, n2, ring A, and B are as described in claim 1; L3 is O; Each X is independently F, Cl, Br, or I.
12. The method for preparing the compound according to claim 1, characterized in that, The compound has the structure shown in formula P1, and the method includes the following steps: Using compounds of formula S1 and S5 as starting materials, a compound having the structure shown in formula P1 was obtained by reaction. The definitions of R1, R2, R3, L1, L2, L4, Y, n1, n2, ring A, and B are as described in claim 1; L3 is O; Each X is independently F, Cl, Br, or I.
13. A pharmaceutical composition, characterized in that, Include: The compound or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1-9; and Pharmaceutically acceptable carrier.
14. Use of the compound according to any one of claims 1-9, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 13, characterized in that, The purpose is as follows: (i) Used in the preparation of GPR84 antagonists; or (ii) Drugs for the preparation of treatments for diseases caused by high expression or excessive excitability of the GPR84 receptor.
15. The use as described in claim 14, characterized in that, The diseases mentioned are multiple sclerosis, inflammatory bowel disease, fibrosis, neurodegenerative diseases, or arthritis.
Citation Information
Patent Citations
Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2013092791A1
Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (GPR84 antagonists)
WO2014095798A1
Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2015197550A1
Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2016169911A1
GPR84 receptor antagonist and use thereof
WO2018161831A1
